Wed, May 22, 2024

top blank header

Gastro Flash Vol-1 No-1, 2015

Gastro Flash Vol-1 No-1, 2015

Non-alcoholic fatty liver disease (NAFLD) is universally considered as the hepatic manifestation of the metabolic syndrome.1Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 2012; 36: 815-23.   It is most commonly associated with insulin resistance/type 2 diabetes mellitus and obesity; and manifested by steatosis, steatohepatitis, cirrhosis, and rarely, hepatocellular carcinoma.2Tolman KG. Dalpiaz AS. Treatment of non-alcoholic fatty liver disease. Therapeutics and Clinical Risk Management 2007:3(6) 1153-63.  
Introduction Irritable bowel syndrome (IBS) is a disorder that can be diagnosed positively on the basis of symptom criteria and evaluation to exclude organic diseases.1Camilleri M, Heading R C & Thompson W G. Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Aliment Pharmacol Ther. 2002; 16: 1407-1430.   Irritable bowel syndrome is among the most commonly encountered chronic functional gastrointestinal (GI) disorders afflicting individuals. Based on the Rome-III criteria abdominal pain accompanied by sustained changes in bowel habit constitute IBS, whose diagnosis is achieved in the absence of biochemical markers of disease. Clinical presentation of constipation, diarrhoea…